178 related articles for article (PubMed ID: 35101233)
1. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain.
DeLiberty JM; Robb R; Gates CE; Bryant KL
Adv Cancer Res; 2022; 153():267-304. PubMed ID: 35101233
[TBL] [Abstract][Full Text] [Related]
2. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the bad eating habits of Ras-driven cancers.
White E
Genes Dev; 2013 Oct; 27(19):2065-71. PubMed ID: 24115766
[TBL] [Abstract][Full Text] [Related]
4. The Metabolic Landscape of RAS-Driven Cancers from biology to therapy.
Mukhopadhyay S; Vander Heiden MG; McCormick F
Nat Cancer; 2021 Mar; 2(3):271-283. PubMed ID: 33870211
[TBL] [Abstract][Full Text] [Related]
5. Autophagy, stress, and cancer metabolism: what doesn't kill you makes you stronger.
Mathew R; White E
Cold Spring Harb Symp Quant Biol; 2011; 76():389-96. PubMed ID: 22442109
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth.
Gaglio D; Metallo CM; Gameiro PA; Hiller K; Danna LS; Balestrieri C; Alberghina L; Stephanopoulos G; Chiaradonna F
Mol Syst Biol; 2011 Aug; 7():523. PubMed ID: 21847114
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Dependencies in RAS-Driven Cancers.
Kimmelman AC
Clin Cancer Res; 2015 Apr; 21(8):1828-34. PubMed ID: 25878364
[TBL] [Abstract][Full Text] [Related]
8. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.
Martinez-Outschoorn U; Sotgia F; Lisanti MP
Semin Oncol; 2014 Apr; 41(2):195-216. PubMed ID: 24787293
[TBL] [Abstract][Full Text] [Related]
10. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.
Lock R; Roy S; Kenific CM; Su JS; Salas E; Ronen SM; Debnath J
Mol Biol Cell; 2011 Jan; 22(2):165-78. PubMed ID: 21119005
[TBL] [Abstract][Full Text] [Related]
11. Exploiting cancer's drinking problem: regulation and therapeutic potential of macropinocytosis.
Puccini J; Badgley MA; Bar-Sagi D
Trends Cancer; 2022 Jan; 8(1):54-64. PubMed ID: 34649835
[TBL] [Abstract][Full Text] [Related]
12. Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.
Clark PM; Mai WX; Cloughesy TF; Nathanson DA
Curr Neurol Neurosci Rep; 2016 Feb; 16(2):17. PubMed ID: 26759318
[TBL] [Abstract][Full Text] [Related]
13. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
14. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
[TBL] [Abstract][Full Text] [Related]
15. KRAS: feeding pancreatic cancer proliferation.
Bryant KL; Mancias JD; Kimmelman AC; Der CJ
Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
[TBL] [Abstract][Full Text] [Related]
16. Uncoupling the Oncogenic Engine.
Schambach A; Schott JW; Morgan MA
Cancer Res; 2017 Nov; 77(22):6060-6064. PubMed ID: 29097608
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer.
Søreide K; Sund M
Cancer Lett; 2015 Jan; 356(2 Pt A):281-8. PubMed ID: 24704294
[TBL] [Abstract][Full Text] [Related]
18. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
Liu X; Ghosh D
Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
[TBL] [Abstract][Full Text] [Related]
19. Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis.
Ramirez C; Hauser AD; Vucic EA; Bar-Sagi D
Nature; 2019 Dec; 576(7787):477-481. PubMed ID: 31827278
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers.
Baker NM; Yee Chow H; Chernoff J; Der CJ
Clin Cancer Res; 2014 Sep; 20(18):4740-6. PubMed ID: 25225063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
